Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

In this episode of The Vitals, we interview 2 nurse practitioners about their key takeaways from the 2022 San Antonio Breast Cancer Symposium (SABCS).

“As time goes [on], we learn more,” says Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCN. Specifically, as more safety data with fam-trastuzumab deruxtecan-nxki (Enerhtu) comes to light, providers are getting a better idea of how to anticipate and handle potentially serious adverse events such as interstitial lung disease and left ventricular dysfunction. Braithwaite, who is an oncology nurse practitioner at the University of Wisconsin Carbone Cancer Center in Madison, highlights exciting developments in HER2-positive breast cancer and for patients with metastatic disease, as well as the potential benefit of oral selective estrogen receptors degraders, throughout the discussion.

Moreover, according to Jamie Carroll, APRN, CNP, MSN, a nurse practitioner at Mayo Clinic in Rochester, Minnesota, data presented at the meeting may change patient conversations in the adjuvant setting. Findings from the POSITIVE (NCT02308085) trial suggest that pausing adjuvant endocrine therapy may be safe for women with hormone receptor–positive breast cancer who wish to pursue pregnancy.

“It's a common discussion that we have and it’s helpful to know that the POSITIVE trial did not see that disrupting endocrine therapy impacted disease outcomes,” Carroll says. “That’s helpful for patients and providers to know that they’re not seeing an increase in recurrence when endocrine therapy is paused to achieve pregnancy.”

Interested in learning more from SABCS? Check out our coverage of the conference here.

We want to hear from you! Which data from SABCS do you think will be practice changing? Email lfischer@mjhlifesciences.com with your feedback.

The Vitals Podcast:

• Sarah Donahue Highlights Destiny-Breast04 Trial Takeaways for Patients With HR+, HER2-Low Metastatic Breast Cancer
• Sri Kota Weighs in On the Evolving Breast Cancer Paradigm

Oncology Nursing News® Online Articles

• Emerging Data Showcases Promising Advancements for Patients With HER2-Low Breast Cancer
• POSITIVE Study Findings Shift Conversations on Pregnancy in ER+ Breast Cancer
• CBD Oil Shows Modest Improvements in Tamoxifen-Related Adverse Effects
• Antidiarrheal Prophylaxis Remains a Key Focus in TKI Treatment for Patients with HER2+ Breast Cancer
• Real-World Data Show Neoadjuvant Pertuzumab/Trastuzumab Increases pCR Rates in HER2+ Breast Cancer

Video Interviews

• Grace Choong and Matthew Goetz On the Impact of Adjuvant Endocrine Therapy Omission in ER+ Positive Breast Cancer

References

• Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX.
• Krop, Ian et al T-DXd yields superior outcomes over chemotherapy-based regimens in patients previously treated with T-DM1 participating in the phase III DESTINY-Breast02 trial. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX.
• Rugo HS, Bardia A, Marmé F, et al. Sacituzumab govitecan vs treatment of physician’s choice: efficacy by Trop-2 expression in the TROPiCS-02 study of patients with HR+/HER2– metastatic breast cancer. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX.
• Hurvitz S, Wang LS, McAndrew NP, et al. TRIO-US B-12 TALENT: neoadjuvant trastuzumab deruxtecan (T-DXd) with or without anastrozole for HER2-low, HR+ early-stage breast cancer. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX.
• Bardia A, Bidard FC, Neven P, et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX.
• Partridge A, Niman SM, Ruggeri M, et al. Pregnancy outcome and safety of interrupting therapy for women with endocrine responsIVE breast cancer: primary results from the POSITIVE trial (IBCSG 48-14 / BIG 8-13). Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX.